You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
For US healthcare professionals only
- Important Safety Information
- Prescribing Information
- Patient Information Leaflet
- For Patients
For US healthcare professionals only
ACCESS RESOURCES & FINANCIAL ASSISTANCE
Learn about Doptelet access options.
See formulary status in your area
Do you have questions on getting access to therapy for your patients related to COVERAGE, PRIOR AUTHORIZATION, OR STEP EDITS?
Consult with your dedicated Field Reimbursement Senior Manager at Doptelet.escalation@sobi.com.
Please include the following information with each email inquiry:
1) Practice Name, 2) Contact Name, 3) Direct Phone Number, 4) State and Zip Code, 5) Issue Needing Assistance
Doptelet Access and Support Resource Guide
Offers a collection of digital resources for HCP office staff to navigate Doptelet access and reimbursement process.
DOWNLOADInside the guide you will find…
Enrollment Guide
Accessing Doptelet Documents
Doptelet Connect offers access and reimbursement support to help patients access Doptelet® (avatrombopag). Doptelet Connect provides information regarding patient healthcare coverage options and financial assistance information that may be available to help patients with financial needs.
For more information, call 1-833-368-2663.
Monday–Friday 8 AM–8 PM ET.
Evaluate a patient’s prescription coverage, including benefits investigation, prior authorization, and appeal assistance support.
Provide field reimbursement support through a single point of contact.
Provide financial assistance information.
Identify potential financial assistance options that may be available to help eligible patients with financial needs.
Answer logistical questions and provide education and coordination around the specialty pharmacy fulfillment process.
Doptelet Copay Assistance Program*
The Doptelet Copay Assistance Program* is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription, up to a maximum of $15,000 per calendar year.
Outlines how the Doptelet Copay Program can help lower out-of-pocket costs for eligible patients receiving Doptelet
Doptelet Patient Assistance Program†
The Patient Assistance Program† provides Doptelet at no cost to patients who meet the eligibility requirements.
View form en español
Doptelet Free Trial Offer†
The Doptelet Free Trial Offer† provides a 15-day supply of Doptelet, at no cost, to patients who are new to Doptelet and have chronic immune thrombocytopenia (cITP). The Free Trial Offer allows physicians and patients to evaluate a patient’s clinical response to Doptelet to determine whether it is the appropriate treatment.
Pharmacies and Distributors
Doptelet prescriptions are filled only through specialty pharmacies in the Doptelet network or by dispensing physician practices. Specialty pharmacies typically mail the patient prescriptions directly to the patient. There are also physician practices that elect to dispense Doptelet through their in-office dispensing pharmacies.
How Doptelet Connect Works
Prescription and Enrollment Form
Prescribes Doptelet and enrolls a patient into Doptelet Connect
View form en español
Describes the Doptelet Connect support offerings available to your patients and your office
Doptelet Connect Process Flow for Healthcare Professional (HCP) Offices
Explains relationship between the HCP offices and Doptelet Connect and the steps each may take during the access process
Authorization provides patient/caregiver access to the Doptelet Connect Patient Support Program
View form en español
In order to participate in the Doptelet Copay Assistance Program (Program), a patient must be ≥18 years and have commercial prescription insurance for Doptelet. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. This offer is not valid for cash-paying patients. The Program is void where prohibited by law. Certain rules and restrictions apply. Sobi reserves the right to revoke, rescind, or amend this offer without notice. This Program is not insurance.
Program subject to eligibility requirement and program terms and conditions.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
